nach oben

Erschienen in:

01.12.2010 | SHORT REPORT

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

verfasst von: Filippo Bellati, Chiara Napoletano, Ilary Ruscito, Maria Pastore, Milena Pernice, Morena Antonilli, Marianna Nuti, Pierluigi Benedetti Panici

Erschienen in: Investigational New Drugs | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Summary

Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8⁺ effector T cells and a reduction of circulating T_reg cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96CrossRefPubMed

Herrinton LJ, Neslund-Dudas C, Rolnick SJ et al (2007) Complications at the end of life in ovarian cancer. J Pain Symptom Manage 34:237–43CrossRefPubMed

Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945–49CrossRefPubMed

Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S (1992) Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 103:1302–06PubMed

Bezwoda WR, Seymour L, Dansey R (1989) Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 64:1029–33CrossRefPubMed

Stuart GC, Nation JG, Snider DD, Thunberg P (1993) Intraperitoneal interferon in the management of malignant ascites. Cancer 71:2027–30CrossRefPubMed

Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P (2001) Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 61:192–6CrossRefPubMed

Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43CrossRefPubMed

Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198:999–1011CrossRefPubMed

10.

Wright JD, Secord AA, Numnum TM et al (2008) A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 18:400–6CrossRefPubMed

11.

El-Shami K, Elsaid A, El-Kerm A (2007) Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 25:9043 (ASCO Meeting Abstracts)

12.

Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS (2008) Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111:530–32CrossRefPubMed

13.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73CrossRefPubMed

14.

Bellati F, Visconti V, Napoletano C et al (2009) Immunology of gynecologic neoplasm: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets 9:541–65CrossRefPubMed

15.

Rustin GJS, Quinn M, Thigpen T et al (2004) Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer). J Natl Cancer Inst 96:487–488PubMed

16.

Rosenberg SM (2006) Palliation of malignant ascites. Gastroenterol Clin North Am 35:189–99CrossRefPubMed

17.

Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM (1983) Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61:189–93PubMed

18.

Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–49CrossRefPubMed

19.

Bamias A, Koutsoukou V, Terpos E et al (2008) Correlation of NK T-like CD3 + CD56+ cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108:421–27CrossRefPubMed

20.

Tamsma JT, Keizer HJ, Meinders AE (2001) Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol 12:1353–57CrossRefPubMed

21.

Schweigert FJ, Raila J, Sehouli J, Buscher U (2004) Accumulation of selected carotenoids, alpha-tocopherol and retinol in human ovarian carcinoma ascitic fluid. Ann Nutr Metab 48:241–45CrossRefPubMed

22.

Bamias A, Tsiatas ML, Kafantari E et al (2007) Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3 + CD56+ cells with platinum resistance. Gynecol Oncol 106:75–81CrossRefPubMed

23.

Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF (2007) Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 13:5643s–5645sCrossRefPubMed

24.

Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S (2009) Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res 29:1787–91PubMed

25.

Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 28:18CrossRefPubMed

26.

Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326–34CrossRefPubMed

27.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S (2009) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. CD005392.

28.

Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–86CrossRefPubMed

29.

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165–71CrossRefPubMed

30.

Mabuchi S, Terai Y, Morishige K et al (2008) Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 14:7781–89CrossRefPubMed

31.

Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM (2006) Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102:134–9CrossRefPubMed

32.

Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76–82CrossRefPubMed

33.

Schultheis AM, Lurje G, Rhodes KE et al (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554–63CrossRefPubMed

34.

Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–14CrossRefPubMed

35.

Nimeiri HS, Oza AM, Morgan RJ et al (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:49–55CrossRefPubMed

36.

Monk BJ, Choi DC, Pugmire G, Burger RA (2005) Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96:902–5CrossRefPubMed

37.

Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA (2006) Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102:140–4CrossRefPubMed

38.

Bidus MA, Webb JC, Seidman JD, Rose GS, Boice CR, Elkas JC (2006) Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 102:5–7CrossRefPubMed

39.

Numnum TM, Rocconi RP, Whitworth J, Barnes MN (2006) The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102:425–8CrossRefPubMed

40.

Arora N, Tewari D, Cowan C, Saffari B, Monk BJ, Burger RA (2008) Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma. Int J Gynecol Cancer 18:369–72CrossRefPubMed

41.

Wright JD, Viviano D, Powell MA et al (2006) Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103:489–93CrossRefPubMed

42.

Kesterson JP, Mhawech-Fauceglia P, Lele S (2008) The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 111:527–29CrossRefPubMed

43.

Micha JP, Goldstein BH, Rettenmaier MA et al (2007) A phase II study of outpatient first-line paclitaxel, carboplatin and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771–76CrossRefPubMed

44.

Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–99PubMed

45.

Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328–35CrossRefPubMed

46.

Alfaro C, Suarez N, Gonzalez A et al (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100:1111–19CrossRefPubMed

47.

Osada T, Chong G, Tansik R et al (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57:1115–24CrossRefPubMed

48.

Wada J, Suzuki H, Fuchino R et al (2009) The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 29:881–8PubMed

49.

Kute TE, Savage L, Stehle JR Jr et al (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 58:1889–98CrossRef

Titel: Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
verfasst von: Filippo Bellati
Chiara Napoletano
Ilary Ruscito
Maria Pastore
Milena Pernice
Morena Antonilli
Marianna Nuti
Pierluigi Benedetti Panici
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2010
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-009-9351-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

Summary

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie